Abstract

Molecular imaging using singlechain variable fragments (scFv) of antibodies targeting cancer specific antigens have been considered a non-immunogenic approach for early diagnosis in the clinic. Usually, production of proteins is performed within Escherichia coli. Recombinant proteins are either expressed in E. coli cytoplasm as insoluble inclusion bodies, that often need cumbersome denaturation and refolding processes, or secreted toward the periplasm as soluble proteins that highly reduce the overall yield. However, production of active scFvs in their native form, without any heterologous fusion, is required for clinical applications. In this study, we expressed an anti-thymocyte differentiation antigen-scFv (Thy1-scFv) as a fusion protein with a N-terminal sequence including 3 × hexa-histidines, as purification tags, together with a Trx-tag and a S-tag for enhanced-solubility. Our strategy allowed to recover ~ 35% of Thy1-scFv in the soluble cytoplasmic fraction. An enterokinase cleavage site in between Thy1-scFv and the upstream tags was used to regenerate the protein with 97.7 ± 2.3% purity without any tags. Thy1-scFv showed functionality towards its target on flow cytometry assays. Finally, in vivo molecular imaging using Thy1-scFv conjugated to an ultrasound contrast agent (MBThy1-scFv) demonstrated signal enhancement on a transgenic pancreatic ductal adenocarcinoma (PDAC) mouse model (3.1 ± 1.2 a.u.) compared to non-targeted control (0.4 ± 0.4 a.u.) suggesting potential for PDAC early diagnosis. Overall, our strategy facilitates the expression and purification of Thy1-scFv while introducing its ability for diagnostic molecular imaging of pancreatic cancer. The presented methodology could be expanded to other important eukaryotic proteins for various applications, including but not limited to molecular imaging.

Highlights

  • Molecular imaging using singlechain variable fragments of antibodies targeting cancer specific antigens have been considered a non-immunogenic approach for early diagnosis in the clinic

  • Molecular imaging has made a considerable contribution to oncology throughout the course of early detection and prognosis, and is an integral part of clinical trials

  • Biomarkers can be detected using various targeted-probes based on antibodies, peptides or proteins, oligonucleotides, or small molecules conjugated to imaging agents for suitable imaging modalities

Read more

Summary

Introduction

Molecular imaging using singlechain variable fragments (scFv) of antibodies targeting cancer specific antigens have been considered a non-immunogenic approach for early diagnosis in the clinic. Producing targeted-ligands as recombinant proteins/antibodies without heterologous tags is needed to generate non-immunogenic agents for translational applications. As a prokaryotic system, E. coli may not be able to produce some eukaryotic proteins in their native f­orm[5] To overcome such issues, strategies include the use of mutated host strains, mRNA enhanced-stability, use of optimal codons, Scientific Reports | (2021) 11:23026. Tag sequences are essential for the expression and purification of recombinant proteins, they can interfere with the structure and function of their fusion partner while limiting their application in the clinic due to immunogenicity. Developing protocols for the recombinant production of eukaryotic proteins in their native form is important

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call